Evidence map›Paper›PMID 42457586›Full record

ArticleChemMedChem2026

COMPASS: A Computational Pipeline to Identify Linkers Predicting Ubiquitinable PROTAC-Induced Ternary Complexes.

Sébastien Sueron, Sayyed Jalil Mahdizadeh, Eric Chevet, Xavier Guillory, François-Hugues Porée, Leif A Eriksson

Abstract read
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sébastien SueronISCR-UMR CNRS 6226, Faculty of Pharmacy, University of Rennes, Rennes, France.ORCID https://orcid.org/0009-0005-6679-694X
Sayyed Jalil MahdizadehDepartment of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.ORCID https://orcid.org/0000-0002-4844-6234
Eric ChevetINSERM U1242, University of Rennes, Rennes, France.ORCID https://orcid.org/0000-0001-5855-4522
Xavier GuilloryINSERM U1242, University of Rennes, Rennes, France.ORCID https://orcid.org/0000-0001-5989-3833
François-Hugues PoréeISCR-UMR CNRS 6226, Faculty of Pharmacy, University of Rennes, Rennes, France.ORCID https://orcid.org/0000-0003-3344-5260
Leif A ErikssonDepartment of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.ORCID https://orcid.org/0000-0001-5654-3109

Funding

Fondation de France 00130853/WB-2022-44441Inserm PCSI 23CP055-00Ligue Contre le CancerSweden Research Council 2019-3684Sweden Research Council 2022-06725Swedish Cancer Foundation 211447-Pj
6 · The paper itself

Abstract

PROteolysis TArgeting Chimeras (PROTACs) are bifunctional molecules designed to induce targeted protein degradation by forming a transient ternary complex between an E3 ubiquitin ligase and a protein of interest (POI), leading to the E3-mediated ubiquitination of the POI and its subsequent proteasomal degradation. Although PROTACs have emerged as highly promising therapeutic tools, rational design remains challenging due to limited structural understanding of the resulting assemblies, the dynamic nature of the ternary interface, and the critical role of the linker. Herein, we present COMPASS (COmputational Modeling of PROTAC Assembly with Structure-based Screening), a computational pipeline that allows the screening of linker libraries by assessing both ternary complex formation and ubiquitination potential. COMPASS functions as a high-sensitivity negative filter, identifying linkers that cannot form productive complexes and enabling their elimination before synthesis. Benchmarking against 20 crystallographic structures yielded <6 Å Cα-RMSD across all systems, outperforming existing methods. Retrospective validation across 8 distinct E3/POI systems (112 PROTACs) yielded 93% recall against degradation endpoints. Discriminative power is strongest when linker geometry is rate-limiting, a regime complementary to the stability and cooperativity effects that static structural modeling cannot capture.

Indexed as

Ubiquitin-Protein LigasesHumansModels, MolecularProteolysisProteolysis Targeting ChimeraUbiquitinUbiquitinationProteolysis Targeting ChimeraUbiquitinUbiquitin-Protein Ligasesdegradationmedicinal chemistrymolecular modelingPROTACternary complexubiquitination

Identifiers

PMID42457586
PMCPMC13372713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.